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trial fibrillation (AF) is the most common arrhythmia.
he clinical events leading to AF are multiple, including
emodynamic, electrophysiologic, ischemic, and metabolic
bnormalities, acting in concert with genetic factors (1).
istological studies (2) have demonstrated the presence of
nflammation in biopsies of patients with isolated AF. It is
ell-established that several cardiovascular diseases, such as
oronary artery disease and hypertension, involve an inflam-
atory mechanism. However, the idea that AF also might
e caused by an inflammatory mechanism is emerging.
-reactive protein (CRP) is an acute-phase reactant that
raditionally has been used to detect acute injury, infection,
nd inflammation and to evaluate the activity of well-known
nflammatory processes, which is why several studies have
sed CRP levels to analyze the level of inflammation in
atients with AF (3–7).
See page 1642
Case-control studies have demonstrated a correlation
etween the levels of CRP and the result of electrical
ardioversion (8). In a study from the group of Rotter et al.
9), patients that maintained sinus rhythm at 3 months after
adiofrequency catheter ablation showed a significant de-
rease in CRP levels.
In this issue of the Journal, Liu et al. (10) have conducted
systematic review and meta-analysis to examine the
ssociation between baseline CRP and recurrence of AF
fter successful electrical cardioversion. Seven prospective
tudies with 420 patients were analyzed. Overall, baseline
RP levels were greater in patients who experience a
ecurrence of AF. The standardized mean difference in the
RP levels between the patients with, and those without
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From the †Arrhythmia Unit, Ramón y Cajal Hospital and ‡Department of
edicine, Alcalá University, Madrid, Spain.F was 0.35 U (95% confidence interval 0.01 to 0.69).
tudies examining the association between CRP and AF
ave been performed but have not yet been systematically
eviewed. Although the number of studies eventually in-
luded in the present meta-analysis is not many, the
ethods, presentation, and conclusion are appropriate. The
rticle is timely and interesting. It provides a reliable
emonstration that CRP is associated with AF and it opens
he door for mechanistic studies and novel AF therapies
argeting inflammation.
However, neither the present meta-analysis nor other
tudies allow a specific determination of causality (cause,
onsequence, or simple association). It could happen that
he beginning of the AF was activated directly by the
nflammation or that the inflammation promoted the be-
inning and the perpetuation of AF. Nevertheless, both
echanisms can be interrelated. The rapid atrial activation,
aused by an automatic focus of pulmonary vein, can
roduce the beginning of apoptosis in the atrial myocytes.
owever, the presence of systemic inflammation with
ncreased levels of CRP could help, in patients with abnor-
ally automatic cells, to develop AF.
The findings must be interpreted carefully because they
ay include a slant of selection and factors of confusion,
any still unknown. There are strong and significantly
ositive associations between CRP levels and several estab-
ished risk factors and comorbidities that can be potential
onfounders, such as smoking, hypertension, body mass
ndex, and diabetes (11). The data published recently by
llinor et al. (12) suggested no difference in CRP levels
mong patients with lone AF compared with healthy
ontrols patients without hypertension. These facts under-
core the importance of evaluating CRP with the use of
rospective data and new, unbiased approaches.
In addition, many studies are based on unique measures
f CRP and, thus, they cannot reflect the inflammatory
rocess throughout the course of time. Another limitation is
he lack of data regarding the parameters of inflammation in
he patients before the beginning of AF, as Liu et al. (10)
eport in the article, and also the methods of AF detection
ere different between the trials and therefore some asymp-
omatic episodes of AF may be overlooked.
Although CRP levels were associated with a high relative
isk of AF recurrence, reading the data, it would add only
ittle improvement to the prediction of risk in an individual
erson. The reason is that the distribution of CRP levels in
atients with or without AF may overlap considerably, as
an be seen from the data of the published studies. It would
e of interest to develop a risk estimation equation, incor-
orating all of the established risk factors for AF and
ecurrences and know the added utility for each one. The
isk stratification is important if it directs us toward the
herapy and resources of greater benefit. However, we have
o bear in mind that there may be considerable differences
etween “an inflammatory marker” a “risk marker” or a “risk
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Editorial Comment April 17, 2007:1649–50actor.” We have to define what exactly CRP is: if CRP is
ssociated with AF by its participation in the causal path-
ay, then it can be a risk factor. It would be a risk marker
f it is statistically associated with AF but need not be
ausally linked; it may be simply a response to other,
stablished, risk factors (e.g., obesity, hypertension, dyslip-
demia) and, thus, the therapeutic strategy also may be
ifferent. Another task would be to establish the link
etween inflammation in AF and the risk of thromboem-
olism through alterations of hemostasis, endothelium,
brinolysis, and platelets.
The relative inefficiency of the present treatments stim-
lates us to dedicate resources to develop new strategies of
reatment for the patients with AF. Drugs like statins as
ell as exercise and weight loss have demonstrated their
ffectiveness in reducing the levels of CRP (13). Similarly,
rugs like inhibitors of the angiotensin-converting enzyme,
ntagonists of the receptors of angiotensin II, among others,
ave shown effectiveness in reducing the recurrence of AF
14). Part of this possible antiarrhythmic effect can be
xplained through its anti-inflammatory activity.
Nevertheless AF, at least in the great majority of cases, is
multifactorial and complex process, and the development
f the substrate for AF requires probably a long period of
ime of evolution. The question remains: What is the mean-
ng of an increased level of CRP in a long and complex
rocess? The exact role placed by CRP in AF needs to be
lucidated by further study. Furthermore, it would be inter-
sting to know the local degree of inflammation at the atrial
evel or in the pulmonary veins, which could not be correctly
ssessed from a systemic point. If the inflammation hypoth-
sis proves to be correct and the management of AF on the
asis of the results of CRP eventually is possible, then
nalysis of cost effectiveness will be required, because AF is
major public health problem, due to its high incidence.
And meanwhile, waiting for more investigations in the
eld of CRP and AF, we must advise our patients all the
easures that we know that diminish the levels of CRP and
he incidence of AF: maintain normal weight or lose weight
f overweight, reduce sodium intake and control hyperten-ion, undertake at least 30 min of physical activity daily, and
o not smoke.
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olmenar Viejo, km 9.100, Madrid 28034, Spain. E-mail:
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